Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Rating of “Buy” by Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received an average recommendation of “Buy” from the eleven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $16.5556.

Several equities research analysts have commented on IVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald began coverage on Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating on the stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning acquired a new stake in Inventiva during the 2nd quarter worth $32,000. Virtu Financial LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at about $60,000. XTX Topco Ltd purchased a new position in shares of Inventiva in the fourth quarter worth about $84,000. Cerity Partners LLC purchased a new position in shares of Inventiva in the fourth quarter worth about $93,000. Finally, NewEdge Advisors LLC acquired a new position in Inventiva during the third quarter worth about $116,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Stock Performance

IVA opened at $4.72 on Wednesday. Inventiva has a twelve month low of $3.35 and a twelve month high of $7.98. The company has a 50-day moving average price of $4.15 and a 200 day moving average price of $5.22.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.